Owen Mumford Announces £14m Investment in New, State-of-the-Art, BREEAM-certified Premises

Owen Mumford, a global leader in the design, manufacture and advancement of medical devices, today announced that work has started on the build of a brand-new, state-of-the-art production facility in Witney, Oxfordshire, UK.

The new building is commissioned to align with the company’s strong sustainability agenda, designed in accordance with the latest environmental standards to obtain BREEAM certification, the world’s leading sustainability assessment for buildings. A ground-breaking ceremony took place to mark the commencement of building work, attended by the Chairman Mark Owen, son of one of the original founders, as well as CEO Jarl Severn.

The £14 million investment project will facilitate the organisation’s ongoing development of innovative medical devices through sustainable design and manufacturing methods. The design of the building will conform to BREEAM certification, which recognises the highest levels of environmental, social and economic sustainability performance, not only protecting natural resources but enhancing the well-being of associates who will be located there. During the planning phase, Owen Mumford has worked closely with ecologist specialists to ensure there has been no negative impact on biodiversity, and targets have been set to show biodiversity gains during and after construction. The latest technology and materials are being used to ensure the effective deployment of energy, heating and cooling.

Owen Mumford’s new Witney site will set a benchmark for world-class design and development in medical devices, establishing a centre of excellence for automation and assembly to deliver a portfolio that drives innovation and growth for the long term. It will also be the location for production of the company’s recently launched, next generation auto-injector Aidaptus®, the industry’s first single-use auto-injector for 1mL and 2.25mL pre-filled syringes as well as its pioneering springless safety syringe Unisafe® and the latest lancets for blood sampling.

“Since we first started to significantly ramp up our sustainability agenda in 2014, we have achieved many important milestones, and today’s ground-breaking ceremony at our new Witney site is a fitting tribute to the journey we are on,” said Jarl Severn, CEO at Owen Mumford. “We are setting the benchmark high for manufacturing to do its part in the overall reduction of environmental impact. Our investment in this new facility supports the promises we make to all our stakeholders by providing the very best platform for innovation in our products, but most importantly by doing it in a truly responsible and ethical way.”

Earlier this year, Owen Mumford achieved B Corp certification after demonstrating strict compliance to the rigorous requirements of the assessment – covering governance, community, workers, environment and customers.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”